Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety

Abstract

The endocannabinoid neurotransmitter, anandamide, has been implicated in the central modulation of stress responses. Previous animal experiments have shown that inhibitors of the anandamide-degrading enzyme, fatty acid amide hydrolase (FAAH), enhance the ability to cope with acute and chronic stress. Here, we investigated the effects of the globally active FAAH inhibitor URB597 in a rat model of predator stress-induced long-term anxiety. Rats exposed to 2,5-dihydro-2,4,5-trimethylthiazoline (TMT), a chemical constituent of fox feces, developed a persistent anxiety-like state, which was assessed 7days after exposure using the elevated plus maze (EPM) test. Systemic administration of URB597 [0.03-0.1-0.3mg/kg, intraperitoneal (ip)] 2h before testing suppressed TMT-induced behaviors with a median effective dose (IC50) of 0.075mg/kg. This effect was strongly correlated with inhibition of brain FAAH activity (r2 = 1.0) and was accompanied by increased brain levels of three FAAH substrates: the endocannabinoid anandamide and the endogenous peroxisome proliferator-activated receptor-α (PPAR-α) agonists, oleoylethanolamide (OEA), and palmitoylethanolamide (PEA). The anxiolytic-like effects of URB597 were blocked by co-administration of the CB1 receptor antagonist rimonabant (1mg/kg, ip), but not of the PPAR-α antagonist GW6471 (1mg/kg, ip). Finally, when administered 18h after TMT exposure (i.e., 6days before the EPM test), URB597 (0.3mg/kg, ip) prevented the consolidation of anxiety-like behavior in a CB1-dependent manner. The results support the hypothesis that anandamide-mediated signaling at CB1 receptors serves an important regulatory function in the stress response, and confirm that FAAH inhibition may offer a potential therapeutic strategy for post-traumatic stress disorder.